ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more
ALTEOGEN Inc (196170) - Total Liabilities
Latest total liabilities as of September 2025: ₩261.55 Billion KRW
Based on the latest financial reports, ALTEOGEN Inc (196170) has total liabilities worth ₩261.55 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ALTEOGEN Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how ALTEOGEN Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ALTEOGEN Inc Competitors by Total Liabilities
The table below lists competitors of ALTEOGEN Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Huagong Tech Co Ltd
SHE:000988
|
China | CN¥10.49 Billion |
|
King Yuan Electronics Co Ltd
TW:2449
|
Taiwan | NT$40.28 Billion |
|
Everest Group Ltd
NYSE:EG
|
USA | $47.05 Billion |
|
Applied Industrial Technologies
NYSE:AIT
|
USA | $1.28 Billion |
|
APA Corporation
NASDAQ:APA
|
USA | $10.84 Billion |
|
Lite-On Technology Corp
TW:2301
|
Taiwan | NT$115.71 Billion |
|
Xero Limited
PINK:XROLF
|
USA | $2.09 Billion |
|
GameStop Corp.
NYSE:GME
|
USA | $5.25 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down ALTEOGEN Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ALTEOGEN Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ALTEOGEN Inc (2014–2024)
The table below shows the annual total liabilities of ALTEOGEN Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩134.92 Billion | +24.63% |
| 2023-12-31 | ₩108.26 Billion | +11.92% |
| 2022-12-31 | ₩96.73 Billion | -21.74% |
| 2021-12-31 | ₩123.61 Billion | +340.77% |
| 2020-12-31 | ₩28.04 Billion | +75.31% |
| 2019-12-31 | ₩16.00 Billion | +236.41% |
| 2018-12-31 | ₩4.76 Billion | +50.08% |
| 2017-12-31 | ₩3.17 Billion | +16.44% |
| 2016-12-31 | ₩2.72 Billion | +226.01% |
| 2015-12-31 | ₩834.62 Million | -60.88% |
| 2014-12-31 | ₩2.13 Billion | -- |